Association of CYP2C19 and UGT1A4 polymorphisms with voriconazole-induced liver injury

被引：11
作者：
Song, Yan [1 ]
Jia, Miao-xin [2 ]
Yang, Guang [3 ]
Feng, Xin-yuan [2 ]
Yin, Dong-hong [1 ]
Kang, Jian-bang [1 ]
Zhao, Qiang [1 ]
Duan, Jin-ju [1 ]
机构：
[1] Shanxi Med Univ, Hosp 2, Dept Pharm, Taiyuan 030001, Peoples R China
[2] Shanxi Med Univ, Sch Pharm, Taiyuan 030001, Peoples R China
[3] Shanxi Med Univ, Hosp 2, Dept Pulm & Crit Care Med, Taiyuan 030001, Peoples R China
来源：
PERSONALIZED MEDICINE | 2020年 / 17卷 / 01期
关键词：
CYP2C19; genetic polymorphism; liver injury; plasma concentration; UGT1A4; voriconazole; CLINICAL-OUTCOMES; JAPANESE PATIENTS; CLOPIDOGREL; PHARMACOKINETICS; HEPATOTOXICITY; METABOLISM; GUIDELINES; DISEASES; IMPACT;
D O I：
10.2217/pme-2019-0042
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Aim: This study investigated the association between voriconazole-induced liver injury and gene polymorphisms of CYP2C19 and UGT1A4. Materials & methods: Thirty-eight adult patients who received voriconazole therapy were included in the study. Genotype of CYP2C19 was detected using gene chip hybrid analysis. The UGT1A4 142T>G was genotyped using PCR-RFLP analysis. Results: Ten patients (26.3%) had voriconazole-induced liver injury and were considered as the case group There was no significant difference between the two groups in genotype and allele frequencies of CYP2C19*2 and UGT1A4 142T>G (p > 0.05), however, the GA frequency of CYP2C19 *3 in the drug-induced liver injury case group was higher than that in the control group (p < 0.05). Compared with patients carrying *1/*1 or *1/*2, there was no significant difference in voriconazole trough concentration of the patients with *1/*3 (p > 0.05). Conclusion: There was no significant correlation between voriconazole-induced liver injury and gene polymorphisms of CYP2C19 and UGT1A4.
引用
收藏
页码：15 / 22
页数：8
相关论文
共 40 条
[1]   Genetic Variations Associated with Anti-Tuberculosis Drug-Induced Liver Injury [J].
Bao Y. ;
Ma X. ;
Rasmussen T.P. ;
Zhong X.-B. .
Current Pharmacology Reports, 2018, 4 (3) :171-181
[2]   PharmGKB summary: voriconazole pathway, pharmacokinetics [J].
Barbarino, Julia M. ;
Obeng, Aniwaa Owusu ;
Klein, Teri E. ;
Altman, Russ B. .
PHARMACOGENETICS AND GENOMICS, 2017, 27 (05) :201-209
[3]   Investigation into UDP-Glucuronosyltransferase (UGT) Enzyme Kinetics of Imidazole- and Triazole-Containing Antifungal Drugs in Human Liver Microsomes and Recombinant UGT Enzymes [J].
Bourcier, Karine ;
Hyland, Ruth ;
Kempshall, Sarah ;
Jones, Russell ;
Maximilien, Jacqueline ;
Irvine, Nicola ;
Jones, Barry .
DRUG METABOLISM AND DISPOSITION, 2010, 38 (06) :923-929
[4]   Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients [J].
Chan, Sze Ling ;
Chua, Angeline Poh Gek ;
Aminkeng, Folefac ;
Chee, Cynthia Bin Eng ;
Jin, Shengnan ;
Loh, Marie ;
Gan, Suay Hong ;
Wang, Yee Tang ;
Brunham, Liam R. .
PLOS ONE, 2017, 12 (10)
[5]  
Chinese Society of Critical Care Medicine, 2007, Chin. J. Intern. Med, V46, P960, DOI [10.3760/j.issn:0578-1426.2007.11.031, DOI 10.3760/J.ISSN:0578-1426.2007.11.031]
[6]   Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events [J].
Chu, Helen Y. ;
Jain, Rupali ;
Xie, Hu ;
Pottinger, Paul ;
Fredricks, David N. .
BMC INFECTIOUS DISEASES, 2013, 13
[7]   Genetic susceptibility to diclofenac-induced hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 genotypes [J].
Daly, Ann K. ;
Aithal, Guruprasad P. ;
Leathart, Julian B. S. ;
Swainsbury, Richard A. ;
Dang, Tarana Singh ;
Day, Christopher P. .
GASTROENTEROLOGY, 2007, 132 (01) :272-281
[8]   Drug-induced liver injury: a safety review [J].
Garcia-Cortes, Miren ;
Ortega-Alonso, Aida ;
Lucena, M. Isabel ;
Andrade, Raul J. .
EXPERT OPINION ON DRUG SAFETY, 2018, 17 (08) :795-804
[9]  
Goodman LS., 2006, GOODMAN GILMANS PHAR, V11th
[10]  
Hao Jin-qi, 2011, Zhonghua Gan Zang Bing Za Zhi, V19, P201, DOI 10.3760/cma.j.issn.1007-3418.2011.03.012
1234